Drug intelligence / Profile preview

BTX-301

Development stage: Preclinical
Lead developer: Human Stem Cells Institute
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

BTX-301 is a recombinant protein-based vaccine being developed for the treatment of cat allergy. Developed by Betuvax, a subsidiary of Artgen (formerly the Human Stem Cells Institute), the vaccine is built on the Betusfera platform, which utilizes a corpuscular adjuvant derived from betulin. BTX-301 is designed as an allergen immunotherapy intended to induce immune tolerance to cat allergens by delivering recombinant proteins that mimic the allergen's structure. It is currently in the discovery and preclinical stages of development.

Beyond the preview

Go deeper on BTX-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BTX-301.

Explore the full profile